JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

A

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Search

Twist Bioscience Corp

Fechado

SetorSaúde

63.31 1.54

Visão Geral

Variação de preço das ações

24h

Atual

Mín

62.92

Máximo

65.68

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-12.47% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

3.8B

Abertura anterior

61.77

Fecho anterior

63.31

Sentimento de Notícias

By Acuity

50%

50%

179 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

23 de abr. de 2026, 00:00 UTC

Notícias Principais

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 de abr. de 2026, 23:33 UTC

Ganhos

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 de abr. de 2026, 22:40 UTC

Ganhos

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 de abr. de 2026, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:11 UTC

Ganhos

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 de abr. de 2026, 21:01 UTC

Ganhos

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

22 de abr. de 2026, 23:46 UTC

Conversa de Mercado

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 de abr. de 2026, 23:34 UTC

Conversa de Mercado
Notícias Principais

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 de abr. de 2026, 23:16 UTC

Ganhos

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 de abr. de 2026, 23:15 UTC

Ganhos

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 de abr. de 2026, 22:54 UTC

Ganhos

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 de abr. de 2026, 22:52 UTC

Ganhos

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 de abr. de 2026, 22:51 UTC

Ganhos

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 de abr. de 2026, 22:31 UTC

Ganhos

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 de abr. de 2026, 22:30 UTC

Ganhos

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 de abr. de 2026, 22:29 UTC

Ganhos

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 de abr. de 2026, 22:28 UTC

Ganhos

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 de abr. de 2026, 22:27 UTC

Ganhos

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 de abr. de 2026, 22:06 UTC

Conversa de Mercado
Ganhos

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 de abr. de 2026, 21:55 UTC

Aquisições, Fusões, Aquisições de Empresas

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 de abr. de 2026, 21:47 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:37 UTC

Ganhos

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 de abr. de 2026, 21:34 UTC

Ganhos

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 de abr. de 2026, 21:29 UTC

Ganhos

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 de abr. de 2026, 21:20 UTC

Conversa de Mercado
Ganhos

Tesla Expands Manufacturing to Chips -- Market Talk

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-12.47% parte inferior

Previsão para 12 meses

Média 54.8 USD  -12.47%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

179 / 348 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat